SLAS Europe 2023 Conference & Exhibition

The SLAS Europe 2023 Conference and Exhibition course package contains 90 presentations including:

46 presentations from four scientific tracks: Biology Unveiled; Frontiers in Technology; Shaping the Future of Therapeutics; Bio-Entrepreneurship in Europe.

2 keynote Speakers: Miguel Alcalde, Susanne Müller-Knapp, Garry Pairaudeau.

37 exhibitor presentations from our Exhibitor Tutorials, Solution Spotlights, and Ignite Award Presentations.

4 presentations from the 1st EUOS/SLAS Joint Challenge.

The SLAS Scientific Program Committee selects conference speakers based on the innovation, relevance and applicability of research as well as those that best address the interests and priorities of today’s life sciences discovery and technology community. All presentations are published with the permission of the presenters.

Use the "Search by Category" bar to filter talk by track.

Purchase of the SLAS Europe Conference and Exhibition package will gain immediate access to all talks from the event. Alternatively, talks can be purchased a la carte.


Search by Category
Search by Format
Sort By
  • Contains 1 Component(s)

    Opening Keynote for Europe 2023

    THE GOLDEN AGE OF DIRECTED EVOLUTION OF ENZYMES. Directed enzyme evolution is leaving a golden age. The consolidation of robust mutant library creation methods and the arise of reliable high-throughput screening assays have allowed scientists all over the world to generate synthetic proteins with functionalities that surpass by far those of natural counterparts. Importantly, he nascent association between Rosetta design and phylogenetic inference methods is assisting directed evolution enterprises. Along these lines, the use of paleoenzymology -ancestral sequence reconstruction and resurrection- aims at opening unexplored avenues for the laboratory evolution of more promiscuous and stable ancestral enzymes. In this lecture, I will discuss all these advances in this fascinating ground of research commenting several case studies from our work on peroxygenase and laccase engineering for the pharma, chemical and environmental sectors.

    Miguel Alcalde

    Full CSIC Professor

    Instituto de Catálisis y Petroleoquímica, ICP, CSIC

    Miguel Alcalde is CSIC Research Professor and founder of EvoEnzyme S.L. (, a spin-off stemming from his research group.

    The central research of Dr. Miguel Alcalde primarily focusses on the engineering of enzymes by directed evolution for a wide range of biotechnological purposes as well as synthetic biology studies for environmental, energy and industrial applications (

    Dr. Alcalde is a biologist by training, with postdoctoral stay at CALTECH in the group of Frances Arnold (Nobel laurate in Chemistry 2018). Coauthor of over 100 articles on enzyme engineering and applied biocatalysis and 14 filled patents, Prof. Alcalde has supervised 35 research projects and 12 PhD Thesis. He was working as a manager of National Research Agency of Spain in the area of biotechnology, (2019-2021) and was in charge of coordinating the section of molecular biotechnology and synthetic biology of SEBBM (Spanish Society of Biochemistry and Molecular Biology, 2017-2020). He is current board member of the Biocatalysis division of the European Federation of Biotechnology (EFB).

  • Contains 1 Component(s)

    Solution Spotlight presentation

    Bionomous - the world's first provider of AI-powered solutions for screening, sorting and dispensing of small biological entities. We are an innovative, agile and conscious team of biologists and engineers working to provide you with an easy-to-use and customizable solution to free up valuable time and increase efficiency.
    Our patented technology was originally created to enable the mechanical sorting of zebrafish eggs. Now, we have adapted this technology to other small biological entities, such as Xenopus laevis oocytes and embryos, killifish and medaka eggs and even flower seeds.
    Come to our talk and discover how our technology can give you better results and more peace of mind!

    Ana Hernando

    COO & co-founder


    Ana obtained her bachelor’s degree in Biology from ‘Universidad Autónoma de Madrid’ (UAM) in 2018. Specialized in Molecular and Cellular Biology, she obtained her master’s in Medical Biology at the ‘Université de Lausanne’ (Unil), with a minor in Neurobiology. Ana has completed several internships throughout her career, related to Oncology (CIEMAT), cardiovascular diseases (CNIC), Pharmacokinetics (DPT, Unil) and Neuroscience (CBMSO and LINE-CHUV); which allows her to have a wide view of the biological research. Ana co-founded Bionomous in 2019, together with Frank Bonner (CEO & co-founder), for the development of laboratory equipments that screen, sort and dispense small biological entities. Ana is currently COO & co-founder at Bionomous where she manages the new applications for the technology, sales and marketing.

  • Contains 1 Component(s)

    Solution Spotlight presentation

    Revvity Solution Spotlight presentation

    Catherine Holland

    Strategy Leader Pharma Research


  • Contains 1 Component(s)

    Solution Spotlight presentation

    Legacy lab automation promises to free up your time so you can focus on your science, but often has the opposite effect of restricting and limiting you. There’s a steep learning curve, high upfront and ongoing costs, and the need to redesign workflows around systems. What if there was a way to put you and your science back at the center of your automation? At Opentrons, we believe there’s a way to help scientists scale their science without having to make huge investments of time and money.
    Join us for this Solutions Spotlight session to learn about something new from Opentrons that is everything today’s lab automation systems are not. It’s flexible — adapting to your protocol. It’s versatile — fitting into any project or workflow your science needs. It’s liberating — releasing scientists from automation systems that overburden their time, reduce their throughput, and limit the scope of their programs.

    Cyndi Woodward

    Director of Product Marketing


    Cyndi leads the product marketing team at Opentrons where she is responsible for driving product strategy grounded in user needs, having joined the organization in 2022. After spending a decade on the bench in life science, clinical diagnostics, and consumer goods industries, Cyndi has held commercial roles in sales and marketing at medical device, clinical diagnostics, and life science organizations over the last ten years.

  • Contains 1 Component(s)

    Solution Spotlight presentation

    In this spotlight presentation, Mike Helme will give an overview of Cell Line Development (CLD) and its current therapeutics focus. He then moves on to the current challenges faced by many biopharma groups in the CLD market. After introducing the UP.SIGHT™, a multifaceted CLD device, he will explain how this platform addresses many of the challenges with its simple user-friendly interface offering the highest level of single-cell assurance. Some very positive data from an industrial partner with the UP.SIGHT™ will be introduced as well. Finally, Mike Helme will discuss how the CLD workflow has been automated within the C.STATION™ platform.

    Mike Helme

    Business Development Exec


    Mike is the CYTENA Sales Executive for Northern Europe. CYTENA is a pioneer in automated single-cell cloning, and the single-cell dispensing technology developed by the company is used by most of the top 20 pharma companies for stable cell line development. Mike Helme joined CYTENA in January 2022 and works with cell line development customers to optimise and accelerate cell line development processes.

  • Contains 1 Component(s)

    Solution Spotlight Presentation

    In this presentation, we will explore how bioprinting technologies address key challenges within drug discovery and drug screening. Bioprinting enables the creation of complex, heterogeneous structures that better mimic in vivo tissue. By precisely controlling the placement and composition of different cell types, scientists can create 3D biomimetic models with more realistic cell-cell interactions, gradients, and microenvironments. Standardized workflows can be developed, reducing time-consuming and repetitive tasks, and enabling more consistent data gathering.
    Join us to learn about the exciting potential of bioprinting technology in advancing disease modeling and drug discovery.

    Pierre-Alexandre Laurent

    Senior Field Application Scientist, Light-based Bioprinting Specialist


    He is Senior Field Application Scientist and Light-based Bioprinting Specialist at CELLINK, company leader in bioprinting technologies.
    After a PhD on the role of PI3-Kinases on the platelet functions and thrombus formation using microfluidic and videomicroscopy technics, he dedicated his postdoc research (Pavia University, Italy) on the development of 3D bone marrow models for the study of thrombocytopenia and ex-vivo platelet production using silk fibroin biomaterial and 3D bioprinting approach.

  • Contains 1 Component(s)

    Solution Spotlight presentation

    Revvity Solution Spotlight presentation

    Long Nguyenq


  • Contains 4 Component(s)

    The EU Open Screen Data Mining Competition Results

    The EU Open Screen Data Mining Competition Results

    Robert Harmel

    Scientific Project and Industry Liaison Manager


    Robert Harmel is a scientific project manager responsible for academic screening projects and industry engagement at EU-OPENSCREEN ERIC, a non-profit European research infrastructure for drug discovery. He studied organic chemistry at Nijmegen University and received a PhD in chemical biology from the Berlin Leibniz Institute for molecular pharmacology in 2020. Robert has experience in organic synthesis and the development of new analytical tools and assays for mass spectrometry, NMR and fluorescence. He is a co-author on 15 peer-reviewed scientific publications and comes with a broad understanding of chemistry, biology and analytics.

    Wenyu Wang


    University of Helsinki

    Wenyu Wanag is a researcher and data scientist working at the University of Helsinki. He has seven years of project experience in applying modern data science techniques to help cancer drug discovery. He is the winner of three international data science competitions on drug targets, drug sensitivity, and patient stratification.

    Andrea Kopp



    Andrea Kopp has been interested in the life sciences since they studied chemistry and biochemistry at the Ludwigs-Maximilians-Universität (LMU) in Munich in 2016. Later, they joined the computer science program at LMU, where they recently finished their Bachelor of Science. In a joint project with Helmholtz Munich and LMU, Andrea compared the performance of different models within the Kaggle challenge: "1st EUOS/SLAS Joint Challenge: Compound Solubility", and developed the winning model. At the SLAS Europe 2023, they present their contribution to the challenge. Currently, Andrea is at the pharmacy department of LMU with a focus on finding novel potent drug candidates with a generative recurrent neural network.

  • Contains 1 Component(s)

    Presentation from the "Biology Unveiled" track

    We are witnessing an exponential increase in the availability of biomedical data and published research findings. Despite this vast and expanding collective dataset, human diseases remain a significant unsolved problem due to limitations in how we translate basic research into effective treatments.

    BenevolentAI has built a Knowledge Graph that integrates large quantities of diverse and independent biomedical data sources - including over 35 million scientific papers, terabytes of genetics and genomics data and the contents of dozens of structured databases - to capture a detailed mechanistic representation of the dysregulated processes that underlie human disease. The Knowledge Graph can be explored or modelled using machine learning tools to uncover novel disease targets. In this talk, Gabriel Rosser will detail the AI-driven process at BenevolentAI to identify therapeutic targets and uncover more effective disease-modifying treatments.

    Gabriel Rosser

    Lead Bioinformatics Data Scientist


    Dr Gabriel Rosser is a lead bioinformatics data scientist at BenevolentAI. He holds a DPhil in mathematical biology from the University of Oxford and spent several years engaged in postdoctoral research applying integrative omics analysis to the study of the brain tumour glioblastoma. His interests include statistical analysis and modelling of genetics and genomics data.

  • Contains 1 Component(s)

    Presentation from the "Shaping the Future of Therapeutics" track

    In the recent decade, chimeric antigen receptor (CAR)-T cell therapy has revolutionized strategies for cancer treatments due to its highly effective clinical efficacy and response for B cell malignancies. Currently, there are six CAR-T cell products available in the market including Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykt. The success of CAR-T cell therapy has stimulated the increase in the research and development of various CAR constructs to target different tumor types. Therefore, a robust and efficient in vitro potency assay is needed to quickly identify potential CAR gene design from a library of construct candidates. In the first part of this work we will expose the drawbacks of the the numerous traditional in vitro CAR-T cell-mediated cytotoxicity assays and demonstrate why image cytometry methodologies have been utilized for various CAR-T cell-mediated cytotoxicity assay using different fluorescent labeling methods, mainly due to their ease-of-use, ability to capture cell images for verification, and higher throughput performance.
    The success of CART has been limited to hematological blood born cancers and the transition into solid tumors has not been as effective as hoped. Immune cell trafficking and immunosuppressive factors within the tumor microenvironment are but two methods that increase the relative difficulty in developing a robust CAR-T cell therapy against solid tumors. In the second part of this work we will highlight why , with the development of 3D spheroid models, image cytometry may provide the necessary tools and applications for CAR T cell therapy discovery geared towards solid tumors.

    Scott Cribbes

    Senior Manager

    Nexcelom from PerkinElmer

    Biochemistry Honours Degree from Glasgow University followed by a PhD in Cancer biology from Beatson Institute for Cancer Research. Five years of research and assay development techniques at British Biotech, Axis Shield and AstraZeneca. Since 2001, I have worked at Applied Biosystems and Life Technologies in the area of imaging, HTS screening, and reagents solutions. Since 2009, I have worked with the Celigo image cytometer technology from development to released product for brightfield capability at Cyntellect to its current 5-channel format at Nexcelom, which continues development within the Perkin Elmer family. The Celigo image cytometer and Nexcelom’s family of cell counters seamlessly fits into the imaging portfolio of Perkin Elmer allowing us to provide scientist with innovative solutions for their research. I have now transitioned into the Market Development leader for Nexcelom products in EMEAI after running the EMEAI business as its development director for tteh last four years.